NEW MJ NEWS

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET.

A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

TerrAscend Corp. (TRSSF) to Delight NJ Shoppers with an Immersive Cookies Experience

TerrAscend to Delight NJ Shoppers with an Immersive Cookies Experience TerrAscend Corp.…

Tauriga Sciences, Inc. (TAUG) Fully Satisfies its Financial Obligations Pursuant to Tauri-Gum Manufacturing Agreement

Tauriga Sciences, Inc. Fully Satisfies its Financial Obligations Pursuant to Tauri-Gum Manufacturing…

Tetra Bio-Pharma Inc. (TBPMF) Opens New Subsidiary in Australia and Provides Regulatory Update

Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update Tetra…

HEXO Corp (HEXO) Announces the Appointment of a New Board Member and Acting CFO

HEXO Announces the Appointment of a New Board Member and Acting CFO…